Fig. 1.
Effects of bolus intraperitoneal administration of QX-314 on bone cancer pain–related behaviors. (A) Time courses of effects of bolus intraperitoneal administration of QX-314 (0.01, 0.1, 1, and 3 mg/kg) or a vehicle on number of flinches. (B) Dose–response relationship of QX-314 with area under the time-effect curve (AUC) of flinches. QX-314 significantly reduced the number of flinches in a dose-dependent manner (A, B). In spontaneous flinches, n = 8 for vehicle; n = 6 for 0.01 mg/kg of QX-314; n = 9 for 0.1, 1, and 3 mg/kg of QX-314. Data for number of flinches and AUC of flinches are presented as means ± SDs. *P < 0.001 versus vehicle, †P < 0.05 versus 0.1 mg/kg of QX-314, ‡P < 0.01 versus 0.1 mg/kg of QX-314, #P ≤ 0.01 versus 0.01 mg/kg of QX-314, and ¶P < 0.05 versus vehicle at each observation point.

Effects of bolus intraperitoneal administration of QX-314 on bone cancer pain–related behaviors. (A) Time courses of effects of bolus intraperitoneal administration of QX-314 (0.01, 0.1, 1, and 3 mg/kg) or a vehicle on number of flinches. (B) Dose–response relationship of QX-314 with area under the time-effect curve (AUC) of flinches. QX-314 significantly reduced the number of flinches in a dose-dependent manner (A, B). In spontaneous flinches, n = 8 for vehicle; n = 6 for 0.01 mg/kg of QX-314; n = 9 for 0.1, 1, and 3 mg/kg of QX-314. Data for number of flinches and AUC of flinches are presented as means ± SDs. *P < 0.001 versus vehicle, †P < 0.05 versus 0.1 mg/kg of QX-314, ‡P < 0.01 versus 0.1 mg/kg of QX-314, #P ≤ 0.01 versus 0.01 mg/kg of QX-314, and ¶P < 0.05 versus vehicle at each observation point.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal